Skip to content

Best of UEG Week 2022: Navigating the Evolving Therapeutic Landscape for IBD
*** Post-Assessment & Claim CME Credit***

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 75% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements. 

There is no fee to participate in this activity.
1.Where are you in your career?(Required.)
2.What is your community of practice?
3.In the analysis of the True North open-label extension, the findings indicated that approximately half the patients who failed to achieve a clinical response after 10 weeks of ozanimod induction treatment benefitted from which of the following:(Required.)
4.Which drug combinations were given in the Phase 2a VEGA proof-of-concept study to show the potential of dual inhibition of interleukin-23 and tumor necrosis factor α to more effectively induce clinical response and remission in patients with moderately severe UC?(Required.)
5.Which of the following patient reported outcome (PRO) questionnaires assesses patient fatigue using a 13-item tool and 5-point scale, where a higher score indicates a better patient outcome?
6.In the U-ACHIEVE Maintenance study, looking at patients with ulcerative colitis who responded to induction therapy with upadacitinib at 8 weeks, which treatment group led to greater clinical remission per adapted Mayo score at week 52 compared to placebo?
EVALUATION FORM
7.Upon completion of this activity, I am able to:
Strongly agree
Agree
Disagree
Strongly disagree
Compare study design and clinical trial benchmarks among relevant studies of UC and CD and their implications for interpreting results.
Describe efficacy and safety data of emerging agents in clinical trials of UC and CD.
Select treatment that optimizes outcomes of patients with UC or CD based on the known safety and efficacy profiles of current therapies.
8.Please indicate the extent of your agreement with the following statements:
Strongly agree
Agree
Disagree
Strongly disagree
The faculty for this activity were effective 
The educational resources provided to me at the educational activity are useful to my practice
9.Overall, was this activity fair, balanced and free from commercial bias?
10.If no, please explain:
11.Of the patients you will see in the next month, about how many will benefit from the information you learned today?
12.Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):
13.Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):
14.For purposes of certification, please complete the following information. *Please note that we will not forward or sell your contact information.*(Required.)
15.I certify that I have participated in the continuing education activity entitled, "Best of UEG Week 2022: Navigating the Evolving Therapeutic Landscape for IBD" and claim 1.0 AMA PRA Category 1 CreditTM.(Required.)
Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate. 

For information about the certification of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Privacy & Cookie Notice